Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.38 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.37 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 2/20 | 0.37 |
| ▸ | HCK | P08631 | 2/20 | 0.37 |
| ▸ | SRC | P12931 | 2/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.37 |
| ▸ | MTOR | P42345 | 2/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.37 |
| ▸ | EPHB4 | P54760 | 2/20 | 0.37 |
| ▸ | PRKDC | P78527 | 2/20 | 0.37 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.37 |
| ▸ | MET | P08581 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25909811 | 0.84 | HSP90AA1 (0.41) | KDM4EALDH1A1GABRG2GABRB3GABRA5 | |
| SCHEMBL25229548 | 0.83 | ALDH1A1 (0.41) | KDM4EALDH1A1GABRG2GABRB3GABRA5 | |
| SCHEMBL31194316 | 0.83 | MET (0.43) | KDM4EALDH1A1GABRG2GABRB3GABRA5 | |
| SCHEMBL31194282 | 0.82 | GABRG2 (0.39) | KDM4EALDH1A1GABRG2GABRB3GABRA5 | |
| SCHEMBL27361311 | 0.81 | MET (0.46) | KDM4EALDH1A1GABRG2GABRB3GABRA5 | |
| SCHEMBL22208408 | 0.80 | AAK1 (0.34) | KDM4EALDH1A1PIK3CAKDRPIK3CD | |
| SCHEMBL29650289 | 0.80 | MET (0.39) | KDM4EALDH1A1GABRG2GABRB3GABRA5 | |
| SCHEMBL19707129 | 0.80 | MET (0.39) | KDM4EALDH1A1GABRG2GABRB3GABRA5 | |
| SCHEMBL559566 | 0.80 | USP30 (0.38) | KDM4EALDH1A1GABRG2GABRB3GABRA5 | |
| SCHEMBL29929897 | 0.80 | USP30 (0.38) | KDM4EALDH1A1GABRG2GABRB3GABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LTD (GB) | 2025-04-10 | — | — | US | disclosed |
| CN-118317950-A | Sulfonamide compounds for the treatment of neurological disorders | 拉里奥治疗有限公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-11-23 | — | — | US | disclosed |
| US-20230234967-A1 | Fused Azole Heterocycles as AHR Antagonists | SAIL BIOMEDICINES, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230234967-A1 | Fused Azole Heterocycles as AHR Antagonists | SAIL BIOMEDICINES, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2023094830-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | LARIO THERAPEUTICS LIMITED (GB) | 2023-06-01 | — | — | WO | disclosed |
| WO-2021242955-A1 | FUSED AZOLE HETEROCYCLES AS AHR ANTAGONISTS | SENDA BIOSCIENCES, INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| US-20200157092-A1 | [1,2,4]-TRIAZOLO [1,5-A]-PYRIMIDINYL DERIVATIVES SUBSTITUTED WITH PIPERIDINE, MORPHOLINE OR PIPERAZINE AS OGA INHIBITORS | Janssen Pharmaceutlca NV (BE) | 2020-05-21 | — | — | US | disclosed |
| WO-2018154133-A1 | [1,2,4]-TRIAZOLO [1,5-A]-PYRIMIDINYL DERIVATIVES SUBSTITUTED WITH PIPERIDINE, MORPHOLINE OR PIPERAZINE AS OGA INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-08-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234967-A1 | Fused Azole Heterocycles as AHR Antagonists | AHR, ARNT, AIPL1 | KDM4E 1678/4885ALDH1A1 799/4885GABRG2 1322/4885 |
| US-20250115569-A1 | SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL CONDITIONS | CACNA1A, CACNA1E, CACNA1S | KDM4E 2441/4885ALDH1A1 3306/4885GABRG2 164/4885 |
| US-20200157092-A1 | [1,2,4]-TRIAZOLO [1,5-A]-PYRIMIDINYL DERIVATIVES SUBSTITUTED WITH PIPERIDINE, MORPHOLINE OR PIPERAZINE AS OGA INHIBITORS | OGA, PSEN1, PSEN2 | KDM4E 1840/4885ALDH1A1 2667/4885GABRG2 2000/4885 |
| US-20230374007-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | RARA, RARG, RARB | KDM4E 551/4885ALDH1A1 72/4885GABRG2 1794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.